San Fernando Valley Business Journal

Simulations Plus Beats Estimates

By Joel Russell Tuesday, January 10, 2017

Simulations Plus reported results that beat expectations.

The Lancaster company, which makes software for pharmaceutical research that simulates a drug’s actions in the body, reported net income of $1.36 million on revenue of $5.4 million during the fiscal first quarter ended Nov. 30. The company had earnings of 8 cents a share, compared to 6 cents for the same quarter last year.

The one analyst who covers the company estimated earnings of 7 cents a share on revenue of $5 million, according to Thomson Financial.

Walt Woltosz, chief executive of Simulations Plus, said fiscal 2017 is off to a good start.

“The pharmaceutical industry continues to adopt simulation and modeling technology to improve productivity and reduce wasted R&D efforts on compounds that would have failed. We expect this trend to continue in 2017, and Simulations Plus is increasingly well-positioned to benefit,” he said in a statement.

Simulations Plus (SLP) announced results after the market closed Monday. Shares closed Tuesday up 45 cents or 4.7 percent to $10 on the Nasdaq.